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Narrow-Band Imaging Bronchoscopy Increases the
Specificity of Bronchoscopic Early Lung Cancer Detection
Felix J. F. Herth, MD,* Ralf Eberhardt, MD,* Devanand Anantham, MRCP,†
Daniela Gompelmann, MD,* Mohamed Wafaa Zakaria, MD,‡ and Armin Ernst, MD*§
Background: Detection of nonsmall cell lung cancer at the
intraepithelial stage is believed to improve cure rates. New
bronchoscopic technologies, including white light videobroncho-
scopy (WLB), autofluorescence imaging (AFI), and narrow band
imaging (NBI), are aiming to diagnose airway neoplasia at a
preinvasive stage.
Objectives: To evaluate the diagnostic yields of NBI individually
and in combination with WLB and AFI.
Methods: A 10-month review of patients who were referred for
airway screening or surveillance. Patients were randomized as to the
order of AFI and NBI examinations. The airway mucosa was graded
endoscopically as “normal,” “abnormal,” “suspicious,” or “tumor.”
All areas that were not normal were biopsied. Biopsies with a
histologic grading of moderate to severe dysplasia or carcinoma in
situ were considered positive for intraepithelial neoplasia.
Results: Sixty-two patients with a mean age of 56.2  9.8 years
were studied. Five patients had invasive cancers and were excluded
from the analysis. The remaining 57 cases had a 30% prevalence of
intraepithelial neoplasia. The sensitivity of WLB was 0.18 and the
specificity was 0.88. The relative sensitivities (compared with WLB)
of AFI and NBI were 3.7 (p  0.005) and 3.0 (p  0.03),
respectively. The relative specificities of AFI and NBI were 0.5 (p
0.001) and 1.0 (p 0.72), respectively. Combining AFI and NBI did
not increase diagnostic yield significantly. The sequence of perform-
ing AFI and NBI did not impact findings.
Conclusions: NBI is an alternative to AFI in the detection of early
lung cancers because it has a comparatively higher specificity
without significantly compromising the sensitivity.
Key Words: Narrow band imaging, Autofluorescence imaging,
White light bronchoscopy, Early lung cancer.
(J Thorac Oncol. 2009;4: 1060–1065)
The stepwise progression of carcinogenesis is believed tobe a potential target for improving the survival of patients
with nonsmall cell lung cancer. Data from other epithelial
organs, such as the cervix, colon, and esophagus, have shown
that the detection of neoplasm at the intraepithelial stage has
resulted in an improved cure rate.1–5 Epithelial changes, such
as high-grade dysplasia and carcinoma in situ (CIS), in the
airways are regarded as squamous cell carcinoma presenting
at an early stage.6–9 These lesions bear the hallmarks of
neoplasia, which are angiogenesis and structural changes of
the mucosa.10 New bronchoscopic technology has targeted
these features of neoplasia to improve the detection of pre-
invasive lesions. Examples of this new technology include
white light videobronchoscopy (WLB), autofluorescence im-
aging (AFI), and narrow band imaging (NBI).
WLB is reflectance imaging of bronchial tissue, which
has been illuminated by white light. The image generated
depends on the reflection, scattering, and absorption of light
by the tissue that is being viewed.11 Although the endoscopic
features of intraepithelial neoplasia have been well described,
the reported sensitivity of conventional bronchoscopy has
been limited.10,12,13 However, the quality of white light bron-
choscopic images has improved with the advent of the video-
bronchoscope. These scopes have a color video chip built into
the tip of the bronchoscope to deliver clearer images.14
Studies of AFI have shown improved sensitivity in the
detection of preinvasive lesions in the airway when compared
with WLB.1,15 An image is generated when blue light (390–
440 nm wavelengths) excites subepithelial cells into produc-
ing a fluorescence light signal that is visually enhanced by
appropriate filtering. This autofluorescence signal is attenu-
ated when blue light is absorbed by hemoglobin or when
thickened mucosa scatters/absorbs the light. AFI exploits
these differences in fluorescence intensity and color tone to
contrast neoplastic tissue from healthy airways.
NBI uses two bandwidths of light: 390 to 445 nm (blue)
light that is absorbed by superficial capillaries and 530 to 550
nm (green) light that is absorbed by blood vessels below the
mucosal capillaries. These narrow bandwidths reduce the
scattering of light (the deeper the light penetrates the mucosa
the stronger the scattering) and enable enhanced visualization
of blood vessels. Previous data have already shown a corre-
lation between mucosal vascular findings and angiogenic
squamous dysplasia.15 Moreover, a pilot study has suggested
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that this technology can detect premalignant lesions not
identified on WLB.16
It is difficult to translate preceding data on WLB and
AFI screening because of the different bronchoscopy systems
used in these studies. Comparative data between NBI and
AFI are also lacking. There are also unanswered questions
over the combined use of AFI together with NBI to comple-
ment each other.
A prospective analysis of an open-label study was
conducted to compare the diagnostic yields of WLB, NBI,
and AFI in the diagnosis of intraepithelial neoplasia. In
evaluating the combined use of these technologies, the se-
quence in which they were used was also studied for any
“memory biases.”
METHODS
All patients referred for airway cancer screening be-
tween March 1, 2005, and December 31, 2005, were re-
viewed. This period was chosen because bronchoscopic pro-
cedures for airway evaluation were performed using a strict
protocol that is described latter. A centralized, computer
filing system ensured that the data during this period was
100% complete. The study was approved by the institutional
review board.
Inclusion Criteria
Patients were considered eligible for inclusion if they
had an indication for bronchoscopy, were at high risk for lung
cancer (but without a known diagnosis), and had no clinical
evidence to suspect central airway malignancies. After they
had signed informed consent for the study protocol, WLB,
AFI, and NBI were performed according to the protocol.
During the study period, all/consecutive patients who were
referred for screening did give informed consent, and adher-
ence to the study protocol was 100% as was evidenced by the
computerized medical records.
Airway Examination and Biopsy
All airway examinations were conducted by attending
interventional pulmonologists, using EVIS EXERAII bron-
choscopes BF-Q180 or BF-1T180 and EVIS LUCERA bron-
choscope BF-F260. Patients had WLB first followed by either
AFI or NBI. The sequence of whether AFI or NBI should be
performed first was determined by a computer-generated
random list. The EVIS EXERA bronchoscope enabled the
endoscopist to switch from WLB to NBI. EVIS LUCERA
BF-F260 bronchoscope (Evis Lucera Spectrum videosystem
with videobronchoscope BF-F260, Olympus Medical Sys-
tems Corp., Tokyo, Japan) was used for AFI. In AFI mode, a
blue excitation light of 390 to 440 nm and a consecutive
green light of 540 to 560 nm passes through the dedicated
filter wheel. The detection wavelength of fluorescence light is
between 470 and 690 nm. The green light band is chosen
because it corresponds to the absorption function of hemo-
globin. Therefore, areas in the airway that have a high blood
content, such as mucosal bleeding and inflammation, will also
have a much higher attenuation of green light. The attenua-
tion of fluorescence light and the attenuation of the green
reflection light are rendered in specific colors, and, therefore,
enhance the distinction between neoplastic lesions (magenta
color) and bleeding or inflammation (dark green) and normal
mucosa (light green).
On AFI, magenta lesions were classified as neoplastic,
dark green lesions as bleeding or inflammation and light
green as normal mucosa. This color scheme is based on what
is generated by the video processor. On the NBI images,
superficial blood vessels appeared brown, and deeper vessels
were cyan.
Abnormalities that were detected by either modality
were graded as 2, abnormal but not suspicious for intraepi-
thelial neoplasia; 3, suspicious for intraepithelial neoplasia;
and 4, tumor. Normal mucosa was graded as “1.” The exact
criteria for classifying each lesion are shown in Table 1. Any
lesion that was not normal when viewed by any of the three
modalities was biopsied with endobronchial biopsy for-
ceps. Two to three biopsies were taken at each site at the
endoscopist’s discretion. If multiple lesions were found in
the same patient, the most distal lesions were biopsied
before the more proximal lesions. A new forceps was used
at each site to avoid cross-contamination. No normal-
appearing bronchial mucosa was biopsied. Biopsies were
performed under the illumination that yielded best visual-
ization of the abnormality.
The primary aim of the trial was to evaluate the value
of NBI to AFI and WLB, not to examine the value of
TABLE 1. Visual Classification of Endobronchial Findings1,11,16,17
Grade WLB AFI NBI
Normal No visual endobronchial abnormality Green image with normal endobronchial
architecture
Normal mucosal vascularity
Abnormal but
not suspicious
Erythema, swelling/thickening of mucosa,
airway inflammation, fibrosis, trauma,
and granulation tissue
Slight decrease in fluorescence, with
poorly defined margins; dark green or
faint magenta image
Increased capillary density and less than 3
criteria present (see below)
Suspicious for
intraepithelial
neoplasia
Nodular, polypoid lesions; irregular
mucosa; focal thickening of subcarina
Definite decrease in fluorescence, with
clearly defined margins; magenta
image; clear distortion of
endobronchial architecture
More than or equal to three criteria present
Capillary loops
Dotted vessels
Complex vascular networks of tortuous vessels
Abrupt ending vessels
Tumor Visible endobronchial tumor Visible endobronchial tumor Visible endobronchial tumor
WLB, white light videobronchoscopy; AFI, autofluorescence imaging; NBI, narrow band imaging.
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bronchoscopy in early lung cancer detection. For this reason,
random biopsies were not effected.
All biopsy specimens were fixed in 10% formalin
solution and interpreted by a dedicated lung pathologist. The
pathologist was blinded to the bronchoscopic findings. All
biopsy specimens were considered evaluable because the
bronchial epithelium was intact in the samples. Specimens
were graded according to the International Histologic Clas-
sification of Tumors of the World Health Organization17 as
either 1, normal; 2, inflammation or bronchitis; 3, reserve-cell
hyperplasia; 4, squamous metaplasia; 5, mild dysplasia; 6,
moderate dysplasia; 7, severe dysplasia; 8, CIS; and 9, inva-
sive carcinoma.
End Points
Any lesion that met the necessary criteria of “suspi-
cious for intraepithelial malignancy” i.e., grade 3 as specified
in Table 1 was classified a positive finding on bronchoscopy
for preinvasive neoplasia. Any biopsy that showed moderate
dysplasia, severe dysplasia, or CIS on histologic analysis was
classified as high-grade dysplasia or premalignant i.e., intra-
epithelial neoplasia (Figures 1A, B and Figures 2A, B). When
evaluating the sensitivities and specificities of combined
modalities (e.g., WLB and AFI), a positive bronchoscopic
result in either one of the procedures was taken as a positive
result for the combined procedure.
A per-patient analysis was used to calculate sensitivi-
ties and specificities for each bronchoscopic modality. If any
patient had multiple lesions, the highest grade lesion was
used to determine the patient’s overall histologic classifica-
tion. When analyzing the impact of the sequence of the
procedures, a per-lesion analysis was used. The “field can-
cerization” and “synchronous tumor” concepts suggest that
each lesion in any given patient is not truly independent of
each other. Despite this limitation, the per-lesion analysis
offered an evaluation into the agreement and disagreement
between AFI and NBI. Furthermore, the detection of each
lesion and processing were carried in an independent manner,
with care to avoid cross-contamination. Specimens from
different sites were also sent to the pathologist separately
even if they were obtained from the same patient.
Statistical Analysis
Statistical analyses were performed using SAS statisti-
cal software (SAS Institute, Cary, NC). Continuous variables
are expressed using mean and standard deviation. Categorical
variables are summarized as counts and percents. Chi-square
test or Fisher’s exact test, as appropriate, was used for
comparing proportions. McNemar’s test was used for evalu-
ating agreement in the per-lesion analysis between the two
procedures. A two-tailed p value of less than 0.05 indicated
statistical significance.
RESULTS
Sixty-two patients met inclusion criteria, from whom
103 separate sites in the airways were biopsied. This
averages out to 1.7 lesions per patient. The mean age was
56.2  9.8 years, with a range of 38 to 81 years, and 28
patients (45%) were women. The indications for bronchos-
copy and the final histologic findings are listed in Table 2.
Five patients had an endobronchial tumor identified on
bronchoscopy. These lesions were identified in all five
cases by WLB, AFI, and NBI; the histologic diagnosis was
squamous cell carcinoma in three patients and adenocar-
cinoma in two patients. Because the aim of this study was
to evaluate the diagnostic yields in detecting intraepithelial
neoplasia and because of the concordance in broncho-
scopic findings among the three bronchoscopic modalities,
these five cases/lesions were excluded from further anal-
ysis. In these patients, no other lesions were biopsied.
The remaining 57 patients had 98 biopsy sites that were
evaluated. There were 17 patients (prevalence of 30%) with
18 biopsy results of either CIS or high-grade dysplasia
(moderate to severe). One of these 17 patients had two
FIGURE 1. Abnormal finding in the autofluorescence mode
(A). In the NBI mode, atypical dotted vessels are visible (B).
The biopsy showed squamous cell cancer.
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separate positive biopsy sites, with one site showing moder-
ate dysplasia and the other site yielding severe dysplasia. The
remaining 40 patients had 80 biopsy sites with histologic
findings of squamous metaplasia or mild dysplasia.
The sensitivity of WLB was 0.18 (95% CI, 0–0.78) and
the specificity was 0.88 (95% CI, 0.76–1.00). The relative
sensitivities (compared with WLB) of AFI and NBI were 3.7
(p  0.005) and 3.0 (p  0.03), respectively. The relative
specificities of AFI and NBI were 0.5 (p  0.001) and 1.0
(p  0.72), respectively. NBI showed a significantly higher
specificity compared with AFI (p  0.001), but no statistical
difference in sensitivity was detected (p  0.49). Combining
the findings of WLB to either AFI or NBI did not change the
relative sensitivity of either procedure (p  1.00). The rela-
tive sensitivity for combined AFI and NBI was 4.0. There
was no statistically significant improvement compared with
either AFI alone or NBI alone. (p  0.56; Table 3)
In the evaluation of the sequence of the procedures,
there were no statistically significant differences between the
sensitivities of either AFI (p  0.63) or NBI (p  0.16) or
combined AFI/NBI (p  1.00), regardless of which broncho-
scopic modality was used first (Figure 3). The specificities of
AFI (p 0.56) or NBI (p 0.78) or combined NBI/AFI (p
0.56) were also independent of the sequence of the proce-
dures used (Figure 4).
There were a total of 40 instances out of 98 where NBI
and AFI disagreed on the findings (p  0.0009), of which in
only one case was NBI positive (true positive) and AFI
negative (severe dysplasia). There were three cases of true
positive AFI and false-negative NBI (all moderate dysplasia),
and there were 36 cases of false-positive AFI and true
negative NBI.
None of the patients suffered any complications related
to the bronchoscopic procedures or the anesthesia used.
DISCUSSION
NBI is a reasonable alternative to AFI in the detection
of early lung cancers because it does not compromise diag-
nostic sensitivity. Both NBI and AFI had superior relative
sensitivities compared with WLB alone, and there was also
no significant difference in the sensitivity between NBI and
AFI. Despite the advances in image clarity, WLB remains an
insensitive diagnostic modality in this field. Combining both
procedures (AFI and NBI) led to a small and nonsignificant
increase in yield. Furthermore, the sequence of the proce-
dures did not impact the sensitivity, and no evidence of any
“memory bias” was detected. Previous data18 have already
shown that the sequence of the procedures between WLB and
AFI is unlikely to influence diagnostic outcome, and this also
seems to be true for NBI and AFI when used in combination.
The sensitivities reported in this study for AFI are
lower than the recent sensitivities reported for other AFI
systems, such as D-light (Karl Storz, Tuttlingen, Germany) of
0.8215; SAFE (Pentax, Tokyo, Japan) of 0.90 to 0.9119,20; and
LIFE (Xilix, Richmond, Canada) of 0.96 to 0.97.14,21 This
discrepancy can be explained by the endoscopic distinction of
lesions into either “abnormal” or “suspicious” and by subse-
quently considering only suspicious lesions as a positive
diagnostic finding on bronchoscopy. This distinction was not
made in all the previous studies.14,15,20–22 If both abnormal and
suspicious lesions were considered together as positive broncho-
scopic findings in this study, then 100% of the high-grade
dysplasia lesions and CIS would have been identified by either
AFI or NBI. This alternative dichotomy of lesions would have
also altered the calculated specificity of both AFI and NBI.
There was no corresponding change in the sensitivity or
specificity of WLB using either grading system for lesions.
This is explained by the fact that all lesions were graded on
WLB as “normal” or suspicious and none met the criteria for
abnormal.
Relative specificity of NBI was found to be almost
equivalent to WLB. However, the specificity of AFI was
significantly lower than either NBI or WLB. Again, combin-
FIGURE 2. Abnormal finding in the white light mode (A).
By NBI, the abrupt ending vessels and same loops are visible
(B). Biopsy results in a carcinoma in situ.
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ing the procedures or the sequence of the procedures did not
impact these findings significantly. There were also no in-
stances of false-positive NBI when AFI was concurrently
negative. Despite using the dual blue and green light bands,
the current AFI system suffers from poor specificity similar to
that in previous trials on AFI (0.26–0.66).1,14,15,19–22 The
only exception in the AFI literature seems to be with dual
digital video-autofluorescence imaging in which case a spec-
ificity of 0.94 has been reported.11 However, in our study,
neither AFI nor NBI identified even a single case of normal
mucosa or bronchitis or inflammation as abnormal or
suspicious. Even with dual digital video-autofluorescence
imaging, some sites of normal mucosa or inflammation
were identified as suspicious.11 Therefore, our findings
suggest that the dual blue and green light AFI technology
does indeed aid in the distinction between inflammatory
and dysplastic epithelium, despite not being highly specific
for high-grade dysplasia or CIS.
Study Limitations
All procedures were performed by bronchoscopists
experienced in the use of AFI and NBI, it is unclear whether
the results would be the same for the occasional user.
In addition, the procedures done in each patient were
done by a single bronchoscopist aware of the findings of
all modalities. It was logistically impossible to arrange for
several bronchoscopists to be available and perform all
modalities independently. Furthermore, random biopsies
were not taken. Therefore, the calculation of the relative
sensitivity is limited.
TABLE 2. Patient Demographics, Indications for Bronchoscopy and Histological Findings by the Order of
AFI/NBI Procedure
AFI Before NBI, n  32 NBI Before AFI, n  30 Overall, n  62
Age (yr)  SD (range) 55.9  9.2 (39–73) 56.5  10.6 (38–81) 56.2  9.8 (38–81)
Gender
Male (%) 17 (53%) 17 (57%) 34 (55%)
Female (%) 15 (47%) 13 (43%) 28 (45%)
Indications for bronchoscopy
Airway evaluation of known NSCLC (%) 19 (59%) 14 (47%) 33 (53%)
Follow-up of previously treated NSCLC (%) 6 (19%) 5 (17%) 11 (18%)
Positive sputum cytology (%) 1 (3%) 5 (17%) 6 (10%)
Screening in smokers with documented COPD (%) 6 (19%) 6 (20%) 12 (19%)
Histology
Squamous metaplasia 13 (41%) 12 (40%) 25 (40%)
Mild dysplasia 11 (34%) 4 (13%) 15 (24%)
Moderate dysplasia 6 (19%) 5 (17%) 11 (18%)
Severe dysplasia 1 (3%) 4 (13%) 5 (8%)
Carcinoma in situ 0 (0%) 1 (3%) 1 (2%)
Invasive carcinoma 1 (3%) 4 (13%) 5 (8%)
AFI, autofluorescence imaging; NBI, narrow band imaging; NSCLC, nonsmall cell lung cancer; COPD, chronic obstructive pulmonary disease.
TABLE 3. Sensitivity, Relative Sensitivity, Specificity, and Relative Specificity of Detecting Lesions That Were Graded as
Moderate to Severe Dysplasia and CIS (Per-Patient Analysis)
WLB AFI WLB  AFI NBI WLB  NBI AFI  NBI WLB  NBI  AFI
Number of patients with
dysplasia (moderate to
severe) and CIS
identified as
bronchoscopically
positive (n  17)
3 11 11 9 9 12 12
Sensitivity (CI) 0.18 (0–0.78) 0.65 (0.39–0.90) 0.65 (0.39–0.90) 0.53 (0.26–0.80) 0.53 (0.39–0.90) 0.71 (0.41–1.00) 0.71 (0.41–1.00)
Relative sensitivity 1.0 3.7 3.7 3.0 3.0 4.0 4.0
Number of patients with
metaplasia and mild
dysplasia identified
as bronchoscopically
negative (n  40)
35 16 14 36 31 16 14
Specificity (CI) 0.88 (0.76–1.00) 0.4 (0.24–0.56) 0.35 (0.06–0.64) 0.90 (0.80–1.00) 0.78 (0.62–0.94) 0.40 (0.13–0.67) 0.35 (0.06–0.64)
Relative specificity 1.0 0.5 0.4 1.0 0.9 0.5 0.4
WLB, white light videobronchoscopy; AFI, autofluorescence imaging; NBI, narrow band imaging; CIS, carcinoma in situ; CI, confidence interval.
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CONCLUSION
Angiogenic squamous dysplasia and its detection by
NBI, using strict bronchoscopic criteria, may be advanta-
geous over AFI screening in detecting early lung cancer. NBI
seems to increase specificity without compromising sensitiv-
ity. This can perhaps be explained by angiogenesis being
more specific than changes in extracellular matrix proteins
and thickening of superficial mucosa in identifying intraepi-
thelial neoplasia.
ACKNOWLEDGMENTS
Micelle Secic from Secic Statistical Consulting, Inc.
provided the statistical analysis.
Olympus Ltd. has supported CME courses at Harvard
University, Thoraxklinik and Singapore General Hospital
through unrestricted educational grants.
REFERENCES
1. Lam S, Kennedy T, Unger M, et al. Localization of bronchial intraepi-
thelial neoplastic lesions by fluorescence bronchoscopy. Chest 1998;
113:696–702.
2. Anderson GH, Boyes DA, Benedet JL, et al. Organisation and results of
the cervical cytology screening programme in British Columbia, 1955–
85. Br Med J (Clin Res Ed) 1988;296:975–978.
3. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer
by colonoscopic polypectomy. The National Polyp Study Workgroup.
N Engl J Med 1993;329:1977–1981.
4. Pech O, May A, Gossner L, et al. Curative endoscopic therapy in
patients with early esophageal squamous-cell carcinoma or high-grade
intraepithelial neoplasia. Endoscopy 2007;39:30–35.
5. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ,
Solomon D; 2006 American Society for Colposcopy and Cervical
Pathology-sponsored Consensus Conference. 2006 consensus guidelines
for the management of women with cervical intraepithelial neoplasia or
adenocarcinoma in situ. Am J Obstet Gynecol 2007;197:340–345.
6. Auerbach O, Stout AP, Hammond EC, Garfinkel L. Changes in bron-
chial epithelium in relation to cigarette smoking and in relation to lung
cancer. N Engl J Med 1961;265:253–267.
7. Bota S, Auliac JB, Paris C, et al. Follow-up of bronchial precancerous
lesions and carcinoma in situ using fluorescence endoscopy. Am J Respir
Crit Care Med 2001;164:1688–1693.
8. Lee P, Sutedja TG. Lung cancer screening: has there been any progress?
Computed tomography and autofluorescence bronchoscopy. Curr Opin
Pulm Med 2007;13:243–248.
9. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new
World Health Organization classification of lung tumours. Eur Respir J
2001;18:1059–1068.
10. Shaipanich T, McWilliams A, Lam S. Early detection and chemopre-
vention of lung cancer. Respirology 2006;11:366–372.
11. Lee P, Brokx HA, Postmus PE, Sutedja TG. Dual digital video-autofluo-
rescence imaging for detection of pre-neoplastic lesions. Lung Cancer
2007;58:44–49.
12. Kato H, Horai T. Color Atlas of Endoscopic Diagnosis in Early Stage
Lung Cancer, 1st Ed. Tokyo: Wolfe publishing, 1992.
13. Woolner LB. Pathology of cancer detected cytologically. In: Atlas of
Early Lung Cancer: National Institute of Health, US Department of
Human Health Services. Tokyo: Igaku-Shoin, 1983.
14. Chhajed PN, Shibuya K, Hoshino H, et al. A comparison of video and
autofluorescence bronchoscopy in patients at high risk of lung cancer.
Eur Respir J 2005;25:951–955.
15. Shibuya K, Hoshino H, Chiyo M, et al. High magnification bronchovid-
eoscopy combined with narrow band imaging could detect capillary
loops of angiogenic squamous dysplasia in heavy smokers at high risk
for lung cancer. Thorax 2003;58:989–995.
16. Vincent BD, Fraig M, Silvestri GA. A pilot study of narrow-band
imaging compared to white light bronchoscopy for evaluation of normal
airways and premalignant and malignant airways disease. Chest 2007;
131:1794–1799.
17. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histolog-
ical typing of lung and pleural tumors with contributions by pathologists
from 14 countries. In: World Health Organization International Histo-
logical Classification of Tumors, XIII, 3rd Ed. Berlin/Heidelberg:
Springer-Verlag, 1999.
18. Hirsch FR, Prindiville SA, Miller YE, et al. Fluorescence versus white-
light bronchoscopy for detection of preneoplastic lesions: a randomized
study. J Natl Cancer Inst 2001;93:1385–1391.
19. Lam B, Wong MP, Fung SL, et al. The clinical value of autofluorescence
bronchoscopy for the diagnosis of lung cancer. Eur Respir J 2006;28:
915–919.
20. Ikeda N, Honda H, Hayashi A, et al. Early detection of bronchial lesions
using newly developed videoendoscopy-based autofluorescence bron-
choscopy. Lung Cancer 2006;52:21–27.
21. Chiyo M, Shibuya K, Hoshino H, et al. Effective detection of bronchial
preinvasive lesions by a new autofluorescence imaging bronchovideo-
scope system. Lung Cancer 2005;48:307–313.
22. Venmans BJ, van der Linden JC, van Boxem AJ, Postmus PE, Smit EF,
Sutedja G. Early detection of pre-invasive lesions in high risk patients:
a comparison of conventional fiberoptic and fluorescence bronchoscopy.
J Bronchol. 1985;5:280–283.
Journal of Thoracic Oncology • Volume 4, Number 9, September 2009 NBI Bronchoscopy and Specificity of Cancer Detection
Copyright © 2009 by the International Association for the Study of Lung Cancer 1065
